Hyderabad: Aurobindo Pharma reported a 32.5% jump in consolidated net profit to ₹1,124 crore for the second quarter ended Sept 30 as compared to ₹848 crore in the same period of last financial year, supported by growth across formulations and active pharmaceutical ingredients (APIs).Revenue from operations for the quarter rose 23.9% to a record ₹10,263 crore from ₹8,286 crore in the corresponding quarter of last year, the company said in a regulatory filing.The US remained Aurobindo’s largest market, with revenue up 25.2% to ₹4,555 crore, helped by integration benefits, base business growth and new launches. Europe revenue increased 27.5% to ₹3,161 crore, accounting for 31% of consolidated revenue. Growth markets rose 16.3% to ₹1,026 crore, while ARV revenue stood at ₹359 crore.Formulations revenue climbed 24.2% to ₹9,102 crore. API revenue grew 20.9% to ₹1,162 crore, aided by a favourable business mix.Aurobindo Pharma vice-chairman and managing director K Nithyananda Reddy said the performance reflects the strength of the company’s business fundamentals, sustained execution and the resilience of its diversified product portfolio.“Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future,” he said.“As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide,” he added.The company received 12 final approvals from the USFDA during the quarter and launched 10 products in the US, including gAdvair and ADQUEY, its first new chemical entity. Aurobindo generated $146 million in free cash flow and reported net cash, including investments, of $189 million. The board declared an interim dividend of ₹7 per share.
